Athenex, inc. announces proposed underwritten public offering of common stock and warrants

Buffalo, n.y., aug. 10, 2022 (globe newswire) -- athenex, inc. (“athenex”) (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. all of the shares of common stock, warrants and pre-funded warrants are being offered by athenex.
ATNX Ratings Summary
ATNX Quant Ranking